A Prospective Pilot Study of Single 19 Gy Fraction High-Dose-Rate Brachytherapy for Favorable-Risk Adenocarcinoma of the ProstateScott Dahlbeck1, Chase C. Hansen1*, Werner deRiese3, A. Robert Kagan4, Carlos Torres1, Maurizio Chiriva-Internati D2, Everardo Cobos2, Jose A. Figueroa2, Diane Nguyen2, Lukman Tijani2 and Jaden D. Evans1,5
- *Corresponding Author:
- Chase C. Hansen
Department of Radiation Oncology
Texas Tech University Health Sciences Center
Lubbock, TX -79415, USA
Tel: (435) 215-3574
E-mail: [email protected]
Received date: January 21, 2015, Accepted date: March 05, 2015, Publication March 09, 2015
Citation: Dahlbeck S, C.Hansen C, deRiese W, Kagan AR, Torres C, et al. (2015) A prospective Pilot Study of Single 19 Gy Fraction High-Dose-Rate Brachytherapy for Favorable-Risk Adenocarcinoma of the Prostate. J Nucl Med Radiat Ther 6:215. doi:10.4172/2155-9619.1000215
Copyright: © 2015 Dahlbeck S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objective: To evaluate the acute genitourinary (GU) and gastrointestinal (GI) toxicities, health-related quality of life (HRQOL) factors, biochemical control rates, and technical feasibility of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer delivered in a single fraction.
Methods: A single-institution, prospective pilot study evaluating 6 patients with low- and intermediate-risk prostate cancer treated in 2013. Patients received a single 19 Gy fraction as HDR monotherapy. Patients were assessed according to the Common Terminology Criteria for Adverse Events version 4.0, the International Index of Erectile Function (IIEF-5), the International Prostate Symptom Score (IPSS), the Expanded Prostate Cancer Index Composite–Bowel Assessment (EPIC-Bowel), a Quality of Life (QOL) Assessment, and an institutionally designed quality of care (QOC) questionnaire. Biochemical failure was defined as a prostate-specific antigen (PSA) nadir plus 2 ng/ml.
Results: Patients tolerated the implant well and were all discharged home the same day by approximately 4 pm. Median follow-up was 9 months. No grade 3, 4 or 5 toxicities were observed. Two of the 6 patients (33%) experienced grade 2 GU toxicity. One patient (17%) experienced grade 2 GI toxicity. HRQOL bowel and urinary assessments revealed a majority of complaints at 3 months, which returned to baseline at 6 months.
Conclusion: HDR brachytherapy as monotherapy for favorable-risk prostate cancer using one implant delivered in a single 19 Gy dose has acceptable acute toxicities and HRQOL reports similar to alternative treatment options.